Praluent (Alirocumab) Safety Signals and FDA Actions

How Alirocumab Works: The PCSK9 Mechanism

Alirocumab is a fully human monoclonal antibody that binds circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity. By neutralizing PCSK9 in the bloodstream, the drug prevents PCSK9 from binding to LDL receptors on hepatocyte surfaces. This means more LDL receptors get recycled back to the cell membrane instead of being degraded.

LDL Receptor Recycling and Cholesterol Clearance

Under normal physiology, PCSK9 binds the LDL receptor after it delivers LDL-C into the hepatocyte, tagging the receptor for lysosomal destruction. Alirocumab interrupts this cycle. The result is a measurable increase in surface LDL receptor density, which accelerates clearance of LDL-C from plasma. In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61% from baseline at 24 weeks compared to placebo, both on top of maximally tolerated statin therapy 1.

Why Mechanism Matters for Safety

The antibody's specificity is relevant to its safety profile. Because alirocumab targets a single extracellular protein rather than interfering with intracellular cholesterol synthesis (as statins do), it avoids myotoxicity pathways linked to HMG-CoA reductase inhibition. This selectivity explains the low rate of musculoskeletal adverse events in trials. The drug does not cross the blood-brain barrier in measurable concentrations, a fact that became central to the neurocognitive safety debate discussed below 2.

FDA Approval Timeline and Regulatory Actions

The FDA approved alirocumab on July 24, 2015 under a priority review designation. The initial indication covered adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond diet and maximally tolerated statin therapy 3.

The 2019 Cardiovascular Indication Expansion

In April 2019, the FDA approved a supplemental Biologics License Application (sBLA) expanding Praluent's indication to include reduction of cardiovascular risk. Specifically, the new label stated alirocumab reduces the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. This expansion rested on results from ODYSSEY OUTCOMES (N=18,924), which demonstrated a 15% relative risk reduction in the composite MACE endpoint (HR 0.85; 95% CI 0.78-0.93; P=0.0003) over a median 2.8 years of follow-up 4.

Dosing Label Revisions

The original approval included only a 150 mg every-two-weeks regimen. Sanofi and Regeneron subsequently obtained FDA approval for a 75 mg every-two-weeks starting dose and a 300 mg every-four-weeks option. These revisions aimed to reduce discontinuation by allowing dose titration based on LDL-C response. The 300 mg monthly pen was approved in April 2017 5.

No Risk Evaluation and Mitigation Strategy (REMS) has been required at any point. The FDA has not issued any boxed warning, Dear Healthcare Professional letter, or safety communication specifically for alirocumab as of the most recent label revision.

Clinical Trial Safety Data: The ODYSSEY Program

The ODYSSEY program encompassed 14 Phase III trials enrolling over 23,000 patients. ODYSSEY OUTCOMES remains the largest and longest, providing the most definitive safety dataset for alirocumab in post-acute coronary syndrome (ACS) patients.

Adverse Event Rates in ODYSSEY OUTCOMES

Among 9,462 patients randomized to alirocumab and 9,462 to placebo, the overall incidence of treatment-emergent adverse events was similar between groups. Discontinuation due to adverse events occurred in 5.3% of alirocumab-treated patients vs. 4.8% on placebo 4.

Specific adverse event rates from the trial:

• Injection site reactions: 3.8% alirocumab vs. 2.1% placebo. Most were mild (erythema, pruritus, swelling) and did not require treatment discontinuation.
• General allergic events: 8.1% alirocumab vs. 7.3% placebo. Severe allergic reactions were rare and balanced between groups.
• Myalgia: 4.1% alirocumab vs. 3.9% placebo. No signal for PCSK9-related myotoxicity.
• Hepatic events: Alanine aminotransferase elevation above 3x the upper limit of normal occurred in 1.3% of both groups.

Very Low LDL-C Observations

A unique aspect of ODYSSEY OUTCOMES was the blinded dose-reduction protocol. When patients achieved two consecutive LDL-C values below 15 mg/dL, the dose was blindly switched to placebo. Approximately 7.7% of alirocumab-treated patients achieved LDL-C <15 mg/dL at some point during the study. Among those reaching very low levels, no excess safety signals were identified for neurocognitive events, hemorrhagic stroke, new-onset diabetes, or hepatic dysfunction 4.

This finding was significant because regulatory agencies and advisory committees had expressed concern about potential harms from extremely low LDL-C concentrations, a concern that predated PCSK9 inhibitor development.

Neurocognitive Safety: The Signal That Did Not Materialize

Early in the PCSK9 inhibitor development program, the FDA flagged neurocognitive adverse events as a potential safety signal. This concern arose from two sources: post-hoc analyses of statin trials suggesting possible cognitive effects, and the theoretical role of cholesterol in neuronal membrane integrity.

The FDA Advisory Committee Discussion

At the June 2015 Endocrinologic and Metabolic Drugs Advisory Committee meeting, FDA reviewers noted a numerical imbalance in neurocognitive events in early ODYSSEY trials (1.2% alirocumab vs. 0.5% placebo). The committee voted unanimously to approve alirocumab but requested continued monitoring 6.

EBBINGHAUS: The Definitive Neurocognitive Study

The EBBINGHAUS trial (N=1,974), a pre-specified cognitive substudy within ODYSSEY OUTCOMES, used validated neuropsychological testing (Cambridge Neuropsychological Test Automated Battery) to assess executive function, working memory, processing speed, and episodic memory over a median of 1.6 years. Results showed no difference between alirocumab and placebo on any cognitive domain. The mean composite cognitive z-score change was -0.01 for alirocumab vs. -0.02 for placebo (P=0.83) 2.

Patients who achieved LDL-C <25 mg/dL showed no worse cognitive performance than those maintaining higher levels. The FDA subsequently updated its safety review, concluding that alirocumab does not appear to cause neurocognitive impairment.

Immunogenicity and Anti-Drug Antibodies

As a biologic, alirocumab carries inherent immunogenicity risk. The FDA label reports that 5.1% of patients in the Phase III program developed anti-drug antibodies (ADAs), compared to 0.6% in placebo groups.

Clinical Significance of ADA Formation

Most antibodies were low-titer and transient. Only 1.2% developed neutralizing antibodies. In patients who developed persistent neutralizing antibodies, LDL-C reductions were attenuated, but no excess injection site reactions, hypersensitivity events, or other safety concerns were identified 5.

Comparison to Evolocumab

The ADA rate for alirocumab (5.1%) is higher than reported for evolocumab (0.3%), likely reflecting differences in assay sensitivity and immunogenicity testing protocols rather than a clinically meaningful distinction. Neither drug has shown loss of efficacy or safety consequences attributable to ADA formation in large-scale trials 7.

Post-Marketing Surveillance and FAERS Data

Since its 2015 approval, alirocumab has been subject to routine pharmacovigilance through the FDA Adverse Event Reporting System (FAERS). The most commonly reported post-marketing adverse events align with the clinical trial database.

Reported Signal Categories

The FDA's quarterly FAERS reviews have not resulted in any new safety signals requiring label changes beyond the original approval. Categories of interest monitored by the FDA include:

• Injection site reactions: Remain the most frequently reported post-marketing event. Most are classified as non-serious.
• Flu-like symptoms: A proportion of patients report nasopharyngitis, sinusitis, and upper respiratory symptoms. In ODYSSEY OUTCOMES, nasopharyngitis occurred in 11.3% of alirocumab patients vs. 11.1% of placebo patients, indicating no drug-attributable excess 4.
• New-onset diabetes: A pre-specified analysis within ODYSSEY OUTCOMES found new-onset diabetes rates of 9.6% with alirocumab vs. 10.0% with placebo (HR 0.96; 95% CI 0.85-1.09), suggesting no diabetogenic signal 8.

No REMS, No Boxed Warning

The absence of a REMS program distinguishes alirocumab from several other injectable biologics. The FDA determined that routine labeling and prescribing information provide adequate risk communication. No MedWatch safety alert has been issued for alirocumab since approval.

Hepatic and Metabolic Safety

Concerns about hepatic safety with lipid-lowering agents trace back to the statin era. Alirocumab's hepatic profile has been consistently reassuring.

Liver Enzyme Data

Across the ODYSSEY program, ALT elevations above 3x the upper limit of normal occurred in 1.7% of alirocumab patients vs. 1.5% of placebo patients. No cases of drug-induced liver injury meeting Hy's law criteria were attributed to alirocumab in any Phase III trial 5.

Vitamin E and Steroid Hormone Levels

Because cholesterol serves as the precursor for steroid hormones and as a carrier for fat-soluble vitamins, regulators assessed whether profound LDL-C lowering might reduce levels of these downstream molecules. In ODYSSEY OUTCOMES, cortisol, DHEA-S, estradiol, testosterone, and vitamin E levels were measured in a subset of patients with LDL-C <25 mg/dL. No clinically relevant decreases were observed 4.

Cardiovascular Safety: Mortality Signal in ODYSSEY OUTCOMES

ODYSSEY OUTCOMES produced a notable secondary finding that merits specific discussion. All-cause mortality was numerically lower in the alirocumab group (3.5%) compared to placebo (4.1%), yielding a hazard ratio of 0.85 (95% CI 0.73-0.98). The nominal P-value was 0.026, but this did not meet the pre-specified hierarchical testing threshold for statistical significance 4.

What the Mortality Trend Means

The result does not constitute proof of a mortality benefit, but it effectively excludes a mortality safety concern. For a lipid-lowering biologic, demonstrating no excess mortality across nearly 19,000 patients over 2.8 years provides strong cardiovascular safety reassurance. The European Society of Cardiology (ESC) and the American College of Cardiology (ACC) have both cited ODYSSEY OUTCOMES in their 2019 and subsequent lipid management guidelines, endorsing PCSK9 inhibitors for high-risk ASCVD patients not at LDL-C goal on maximally tolerated statin plus ezetimibe therapy 9.

Special Populations and Ongoing Monitoring

Pregnancy and Lactation

Alirocumab is classified as not recommended during pregnancy. LDL-C and other lipids increase physiologically during gestation, and the effects of PCSK9 inhibition on fetal development are unknown. No controlled human studies exist. Animal reproduction studies at doses up to 75 mg/kg showed no fetal harm, but the FDA label advises discontinuation in patients who become pregnant 5.

Pediatric Use

The FDA has not approved alirocumab for patients under 18 years of age. A Phase III study (ODYSSEY KIDS, NCT03510845) evaluating alirocumab in pediatric HeFH patients aged 8 to 17 is registered. Data from this trial will inform a potential pediatric labeling supplement 10.

Renal and Hepatic Impairment

No dose adjustment is required for mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m²) or mild hepatic impairment. Alirocumab has not been studied in severe renal impairment, dialysis patients, or moderate to severe hepatic impairment. Given that monoclonal antibodies are cleared primarily through proteolytic catabolism rather than renal or hepatic metabolism, significant pharmacokinetic changes in these populations are not expected.

How Alirocumab Compares to Evolocumab in Safety

Both PCSK9 inhibitors share a class-level safety profile. FOURIER (evolocumab, N=27,564) and ODYSSEY OUTCOMES (alirocumab, N=18,924) are the two landmark cardiovascular outcome trials. Injection site reactions, the most common adverse event for both, occurred at similar rates (2.1% evolocumab vs. 3.8% alirocumab, though cross-trial comparison is unreliable due to differing assessment methods) 7. Neither drug showed excess new-onset diabetes, myopathy, hepatotoxicity, or confirmed neurocognitive impairment.

The key difference is that ODYSSEY OUTCOMES demonstrated the mortality trend favoring alirocumab (HR 0.85), while FOURIER did not (HR 1.04; 95% CI 0.91-1.19). Whether this reflects patient population differences (post-ACS vs. Stable ASCVD), the blinded dose-reduction protocol in ODYSSEY, or chance remains debated.

Patients switching between PCSK9 inhibitors should expect comparable safety profiles, though individual tolerability (injection pain, ADA formation) may vary.